These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 26036811)
1. The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. Davenport C; Mahmood WA; Forde H; Ashley DT; Agha A; McDermott J; Sreenan S; Thompson CJ; McGrath F; McAdam B; Cummins PM; Smith D Eur J Endocrinol; 2015 Jul; 173(1):53-61. PubMed ID: 26036811 [TBL] [Abstract][Full Text] [Related]
2. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818 [TBL] [Abstract][Full Text] [Related]
3. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. Rizzo M; Abate N; Chandalia M; Rizvi AA; Giglio RV; Nikolic D; Marino Gammazza A; Barbagallo I; Isenovic ER; Banach M; Montalto G; Li Volti G J Clin Endocrinol Metab; 2015 Feb; 100(2):603-6. PubMed ID: 25393640 [TBL] [Abstract][Full Text] [Related]
4. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Olesen P; Nguyen K; Wogensen L; Ledet T; Rasmussen LM Am J Physiol Heart Circ Physiol; 2007 Feb; 292(2):H1058-64. PubMed ID: 17056676 [TBL] [Abstract][Full Text] [Related]
5. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results. Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443 [TBL] [Abstract][Full Text] [Related]
6. Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660 [TBL] [Abstract][Full Text] [Related]
7. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day? Simpson R; King A Expert Rev Clin Pharmacol; 2015 Mar; 8(2):179-88. PubMed ID: 25697410 [TBL] [Abstract][Full Text] [Related]
8. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456 [TBL] [Abstract][Full Text] [Related]
9. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M; Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856 [TBL] [Abstract][Full Text] [Related]
11. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2]. Jahn E; Sausele T Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303 [TBL] [Abstract][Full Text] [Related]
12. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Montanya E; Sesti G Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994 [TBL] [Abstract][Full Text] [Related]
13. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes. Gross B J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146 [TBL] [Abstract][Full Text] [Related]
14. Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study. Yamamoto S; Hayashi T; Ohara M; Goto S; Sato J; Nagaike H; Fukase A; Sato N; Hiromura M; Tomoyasu M; Nakanishi N; Lee S; Osamura A; Yamamoto T; Fukui T; Hirano T Diabetes Res Clin Pract; 2018 Jun; 140():339-346. PubMed ID: 29588170 [TBL] [Abstract][Full Text] [Related]
15. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes. Ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Drent ML; Diamant M; IJzerman RG Diabetes Care; 2016 Feb; 39(2):214-21. PubMed ID: 26283736 [TBL] [Abstract][Full Text] [Related]